Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465578 | 1.00 | KDM1A (0.52) | KDM1AEGFRIRAK1IRAK4KDM4E | |
| SCHEMBL18676689 | 1.00 | KDM1A (0.52) | KDM1AEGFRIRAK1IRAK4KDM4E | |
| SCHEMBL3952560 | 0.94 | EGFR (0.48) | KDM1AEGFRIRAK1IRAK4KDM4E | |
| SCHEMBL6592222 | 0.89 | KDM1A (0.56) | KDM1AEGFRIRAK1IRAK4KDM4E | |
| SCHEMBL10296328 | 0.89 | KDM1A (0.56) | KDM1AEGFRIRAK1IRAK4KDM4E | |
| SCHEMBL19060471 | 0.85 | SMN1; SMN2 (0.45) | EGFRHTTMAPK1 | |
| SCHEMBL21884844 | 0.85 | KDM1A (0.53) | KDM1AEGFRIRAK1IRAK4KDM4E | |
| SCHEMBL13271522 | 0.85 | KDM1A (0.53) | KDM1AEGFRIRAK1IRAK4KDM4E | |
| SCHEMBL29492471 | 0.84 | PDGFRB (0.55) | EGFRLCKPDGFRBPDGFRA | |
| SCHEMBL165285 | 0.84 | PDGFRB (0.55) | EGFRLCKPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106946774-B | The preparation method of 7- benzyloxy-6-methoxyl-4-hydroxyquinoline | 嘉兴学院 | 2019-08-09 | — | — | CN | claimed |
| CN-106946774-A | The preparation method of the oxyquinoline of 7 benzyloxy, 6 methoxyl group 4 | 嘉兴学院 | 2017-07-14 | — | — | CN | claimed |
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-111253385-B | Heterocyclic compound, preparation method and application | 遵义医科大学珠海校区 | 2023-11-24 | — | — | CN | disclosed |
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006117552-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-0853115-A1 | Additive concentrates containing mixtures of organic diluents and esterified carboxy-containing interpolymers and lubricants containing them | The Lubrizol Corporation (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0848053-A1 | Mixtures of esterified carboxy-containing interpolymers and lubricants containing them | The Lubrizol Corporation (US) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | KDM1A 1037/4885EGFR 124/4885IRAK1 1363/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | KDM1A 1037/4885EGFR 124/4885IRAK1 1363/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | KDM1A 1037/4885EGFR 124/4885IRAK1 1363/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | KDM1A 334/4885EGFR 1308/4885IRAK1 1000/4885 |
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | KDM1A 4368/4885EGFR 218/4885IRAK1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.